CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25979924.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2555.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epigenetic targets have emerged as an exciting area for drug discovery. The discovery that histone deacetylase (HDAC) inhibitors had marked anticancer activity in T-cell lymphoma gave impetus to the field. In a phase I study published in Clinical Cancer Research in March 2002, romidepsin (depsipeptide), a potent HDAC inhibitor, was found to be tolerable, with a side effect profile that was later understood to be characteristic of this class of agents. Evidence of activity in this key phase I trial provided momentum for the further study of epigenetic agents.
Medical subject headings
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Depsipeptides
- Enzyme Inhibitors
- Histone Deacetylase Inhibitors
- Neoplasm Recurrence, Local
- Neoplasms
- Peptides, Cyclic